These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 25587280)
1. Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Park M; Rafii F Int J Microbiol; 2014; 2014():456979. PubMed ID: 25587280 [TBL] [Abstract][Full Text] [Related]
2. Effect of fluoroquinolone resistance selection on the fitness of three strains of Clostridium perfringens. Park M; Sutherland JB; Kim JN; Rafii F Microb Drug Resist; 2013 Dec; 19(6):421-7. PubMed ID: 23789809 [TBL] [Abstract][Full Text] [Related]
3. Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens. Park S; Park M; Rafii F BMC Microbiol; 2013 Mar; 13():50. PubMed ID: 23452396 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the metabolic activities of four wild-type Clostridium perfringens strains with their gatifloxacin-selected resistant mutants. Rafii F; Park M; Gamboa da Costa G; Camacho L Arch Microbiol; 2009 Dec; 191(12):895-902. PubMed ID: 19855959 [TBL] [Abstract][Full Text] [Related]
6. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. Adams DA; Riggs MM; Donskey CJ Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibilities of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995. Knapp JS; Wongba C; Limpakarnjanarat K; Young NL; Parekh MC; Neal SW; Buatiang A; Chitwarakorn A; Mastro TD Sex Transm Dis; 1997 Mar; 24(3):142-8. PubMed ID: 9132980 [TBL] [Abstract][Full Text] [Related]
8. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Rafii F; Park M; Novak JS Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722 [TBL] [Abstract][Full Text] [Related]
9. Substitutions of amino acids in alpha-helix-4 of gyrase A confer fluoroquinolone resistance on Clostridium perfringens. Rafii F; Park M Arch Microbiol; 2007 Feb; 187(2):137-44. PubMed ID: 17051403 [TBL] [Abstract][Full Text] [Related]
10. Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens. Rafii F; Park M; Bryant AE; Johnson SJ; Wagner RD Antimicrob Agents Chemother; 2008 Mar; 52(3):895-900. PubMed ID: 18160514 [TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743 [TBL] [Abstract][Full Text] [Related]
12. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458 [TBL] [Abstract][Full Text] [Related]
13. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV. Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166 [TBL] [Abstract][Full Text] [Related]
14. Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. Hayward CL; Erwin ME; Barrett MS; Jones RN Diagn Microbiol Infect Dis; 1999 Jun; 34(2):99-102. PubMed ID: 10354858 [TBL] [Abstract][Full Text] [Related]
15. Exposure to β-lactams results in the alteration of penicillin-binding proteins in Clostridium perfringens. Park M; Rafii F Anaerobe; 2017 Jun; 45():78-85. PubMed ID: 28185856 [TBL] [Abstract][Full Text] [Related]
16. Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi. Rafii F; Park M; Wynne R Chemotherapy; 2005 Aug; 51(5):256-62. PubMed ID: 16088123 [TBL] [Abstract][Full Text] [Related]
17. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428 [TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Fukuda H; Hori S; Hiramatsu K Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384 [TBL] [Abstract][Full Text] [Related]
19. Characterization of an ATP-binding cassette from Clostridium perfringens with homology to an ABC transporter from Clostridium hathewayi. Rafii F; Park M; Carman RJ Anaerobe; 2009 Aug; 15(4):116-21. PubMed ID: 19655423 [TBL] [Abstract][Full Text] [Related]